clinical trial · NCT05630768
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Dong-A ST Co., Ltd.·phase4·completed·n = 149
Postmenopausal OsteoporosisRisedronate Sodium 35 MG [Actonel]Calcium Vitamin D combination
brief summary
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
started
Jan 3, 2023
primary completion
Jul 23, 2025
completion
Jul 23, 2025
last updated
Aug 24, 2025
official title
A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol